{
  "id": 13509693,
  "title": "Zymeworks EVP Adam Schayowitz sells $357,557 in ZYME stock for taxes",
  "url": "https://urgent.news/2026/10/10/zymeworks-evp-adam-schayowitz-sells-357-557-in-zyme-stock-for-taxes",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-10T19:16:00.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/zymeworks-evp-adam-schayowitz-sells-357557-in-zyme-stock-for-taxes-93CH-4942216"
  },
  "original_language": "en",
  "account": null,
  "summary": "Executive Vice President and Head of Research & Development at Zymeworks Inc., Adam Schayowitz, sold 13,832 shares of the company's common stock on October 9, 2026, amounting to $357,557 to cover tax obligations. This sale, which occurred upon the vesting of restricted stock units (RSUs), was a mandatory transaction and not a discretionary one. The shares were sold at prices ranging from $25.85 to $25.88, with a weighted average price of $25.85 per share. Despite the recent sale, Zymeworks remains an attractive investment according to analysts, who maintain a bullish outlook on the company with price targets ranging from $32 to $60. The stock currently trades at $25.79, up 42.8% over the past year. Other recent developments include Zymeworks' acquisition of Theravance Biopharma, which has received positive evaluations from investment firms, and FDA approval for two Ziihera-containing regimens for treating HER2-positive gastroesophageal adenocarcinoma.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}